Michael Vickers

Michael is a graduate of the University of New Mexico’s Anderson Schools of Management with a BBA in Financial Management. Vickers manages the day-to-day operations for Maas Biolab, LLC and oversees the company’s several ongoing drug development projects including good manufacturing practices production of Maas Biolab’s cyclosporine formulation Mitogard(R), good laboratory practices dose range finding toxicology studies and compilation of an Investigational New Drug (IND) application under the company’s current SBIR project. Mr. Vickers co-authored Maas Biolab’s successful grant proposals including a National Institutes of Health (NIH) fast-track SBIR grant as well as a Fort Detrick Tech Transfer Initiative grant. Michael also managed the company’s Defense Threat Reduction Agency (DTRA) contract studying the brain penetration and effectiveness of cyclosporine in models of nerve agent exposure.